Power considerations when a continuous outcome variable is dichotomized

DOI10.1080/10543409808835243zbMath0914.62093OpenAlexW1983942635WikidataQ52242987 ScholiaQ52242987MaRDI QIDQ4224616

Andrzej S. Kosinski, Steve M. Snapinn, Ben A. Deyi

Publication date: 23 June 1999

Published in: Journal of Biopharmaceutical Statistics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/10543409808835243

zbMATH Keywords

continuousdichotomizedLovastatin Restenosis Trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Parametric hypothesis testing (62F03) Medical applications (general) (92C50)

Related Items (5)

New Exact and Asymptotically Optimal Solution to the Behrens-Fisher Problem, with Tables ⋮ A sequential modeling approach for predicting clinical outcomes with repeated measures ⋮ Selection of a statistical analysis method for the Glasgow Outcome Scale‐Extended endpoint for estimating the probability of favorable outcome in future severe <scp>TBI</scp> clinical trials ⋮ Comparison of dichotomized and distributional approaches in rare event clinical trial design: a fixed Bayesian design ⋮ Dichotomous transformations for statistical inference about odds ratios

Cites Work

• Use of tail areas for testing goodness-of-fit

This page was built for publication: Power considerations when a continuous outcome variable is dichotomized